
A
GDSC1/2-trained predictions, TCGA
GDSC1/2-trained predictions, GSE99420
#1
#2
#3
#4
MK-1775
WEHI-539
UMI-77
SGC-CBP30
EPZ5676
Paclitaxel
OSI-930
CCT007093
Motesanib
EPZ004777
Docetaxel
AZD5991
PRIMA-1MET
Vinorelbine
Bryostatin 1
EHT-1864
PHA-793887
GSK-LSD1-2HCl
Vinblastine
PFI3
Docetaxel
AZD6738
YK-4-279
Rucaparib
KRAS (G12C) Inhibitor-12
Sabutoclax
WZ3105
AZD7762
GSK690693
GSK2830371A
Ara-G
Niraparib
CD532
UNC0638
eEF2K Inhibitor, A-484954
ML323
5-azacytidine
Fulvestrant
Wee1 Inhibitor
A-366
IWP-2
GDC0810
LGK974
Pemetrexed
Fulvestrant
Ispinesib Mesylate
Alpelisib
Nelarabine
XMD13-2
Entinostat
LMB_AB2
Tubastatin A
ARRY-520
Fludarabine
RO-3306
Dactinomycin
GSK3337463A
GSK2830371
CPI-637
MK-8776
Veliparib
C-75
VE-822
Nilotinib
LY2109761
NSC319726
Telomerase Inhibitor IX
CI-1040
Midostaurin
IGFR_3801
PD173074
BAY AKT1
AZ628
Selumetinib
TANK_1366
Alisertib
BAM7
Saracatinib
Ponatinib
PARP_9495
Dasatinib
Tivozanib
TGX221
FGFR_3831
Ulixertinib
FGFR_0939
PD0325901
HG6-64-1
I-BET-151
EphB4_9721
PI-103
THR-103
AZD3759
Cetuximab
Venotoclax
Venetoclax
LDN-193189
TAF1_5496
Quizartinib
cancer sample
cancer sample
Z-score
-3
-2
-1
0
1
2
3
sex hormones
growth factor
cell cycle checkpoint
apoptosis
epigenetics
transcription translation
DNA synthesis
adhesion cytoskeleton
B
Vinblastine, TCGA
η² = 0.6, p < 0.001
Ponatinib, TCGA
η² = 0.65, p < 0.001
Venetoclax, TCGA
η² = 0.46, p < 0.001
Vinblastine, GSE99420
η² = 0.4, p < 0.001
Ponatinib, GSE99420
η² = 0.48, p < 0.001
Venetoclax, GSE99420
η² = 0.33, p < 0.001
predicted log IC50 [μM]
#1 n = 24
#2 n = 63
#3 n = 27
#4 n = 35
#1 n = 7
#2 n = 30
#3 n = 5
#4 n = 18